135 related articles for article (PubMed ID: 34288715)
1. Percentage of Teratoma in Orchiectomy and Risk of Retroperitoneal Teratoma at the Time of Postchemotherapy Retroperitoneal Lymph Node Dissection in Germ Cell Tumors.
Calaway AC; Kern SQ; Crook D; Tong Y; Masterson TA; Adra N; Einhorn LH; Foster RS; Cary C
J Urol; 2021 Dec; 206(6):1430-1437. PubMed ID: 34288715
[TBL] [Abstract][Full Text] [Related]
2. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.
Dusaud M; Malavaud B; Bayoud Y; Sebe P; Hoepffner JL; Salomon L; Houlgatte A; Pignot G; Rigaud J; Fléchon A; Pfister C; Rouprêt M; Soulié M; Méjean A; Durand X
J Surg Oncol; 2016 Dec; 114(8):992-996. PubMed ID: 27859263
[TBL] [Abstract][Full Text] [Related]
3. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
[No Abstract] [Full Text] [Related]
4. Patient selection for retroperitoneal lymph node dissection after chemotherapy for nonseminomatous germ cell tumors.
Herr HW; Toner GC; Geller NL; Bosl GJ
Eur Urol; 1991; 19(1):1-5. PubMed ID: 1848821
[TBL] [Abstract][Full Text] [Related]
5. Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer.
Beck SD; Foster RS; Bihrle R; Ulbright T; Koch MO; Wahle GR; Einhorn LH; Donohue JP
J Urol; 2002 Oct; 168(4 Pt 1):1402-4. PubMed ID: 12352402
[TBL] [Abstract][Full Text] [Related]
6. Delayed orchiectomy at postchemotherapy retroperitoneal lymph node dissection due to laterality of retroperitoneal metastatic pattern consistent with testicular primary: assessment of pathologic findings.
Brown JA; Bihrle R; Foster RS
Urology; 2008 May; 71(5):911-4. PubMed ID: 18342916
[TBL] [Abstract][Full Text] [Related]
7. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.
Carver BS; Shayegan B; Eggener S; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Oct; 25(28):4365-9. PubMed ID: 17906201
[TBL] [Abstract][Full Text] [Related]
8. Results of retroperitoneal lymph node dissection after chemotherapy in patients with pure seminoma in the orchidectomy specimen but elevated serum alpha-fetoprotein.
Peterson M; Beck S; Bihrle R; Einhorn L; Foster R
BJU Int; 2009 Jul; 104(2):176-8. PubMed ID: 19493258
[TBL] [Abstract][Full Text] [Related]
9. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD
Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394
[TBL] [Abstract][Full Text] [Related]
10. Testicular Radiomics To Predict Pathology At Time of Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Tumor.
Venishetty N; Taylor J; Xi Y; Howard JM; Ng YS; Wong D; Woldu SL; De Leon AD; Pedrosa I; Margulis V; Bagrodia A
Clin Genitourin Cancer; 2024 Feb; 22(1):33-37. PubMed ID: 37468341
[TBL] [Abstract][Full Text] [Related]
11. Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen.
Dowling CM; Assel M; Musser JE; Meeks JJ; Sjoberg DD; Bosl G; Motzer R; Bajorin D; Feldman D; Carver BS; Sheinfeld J
Urology; 2018 Apr; 114():133-138. PubMed ID: 29410311
[TBL] [Abstract][Full Text] [Related]
12. Postchemotherapy retroperitoneal lymph node dissection in patients presenting with very high HCG levels.
Speir RW; Calaway AC; Einhorn LH; Foster RS; Cary C
Urol Oncol; 2020 Aug; 38(8):687.e19-687.e23. PubMed ID: 32448503
[TBL] [Abstract][Full Text] [Related]
13. A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma.
Leão R; Nayan M; Punjani N; Jewett MAS; Fadaak K; Garisto J; Lewin J; Atenafu EG; Sweet J; Anson-Cartwright L; Boström P; Chung P; Warde P; Bedard PL; Bagrodia A; Freifeld Y; Power N; Winquist E; Hamilton RJ
Eur Urol Focus; 2018 Dec; 4(6):995-1001. PubMed ID: 29428550
[TBL] [Abstract][Full Text] [Related]
14. Primary vs. post-chemotherapy retroperitoneal lymph node dissection (RPLND) in patients with presence of teratoma at orchiectomy.
Williams SB; Kacker R; Steele GS; Richie JP
Urol Oncol; 2012; 30(1):60-3. PubMed ID: 20189842
[TBL] [Abstract][Full Text] [Related]
15. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection.
Carver BS; Bianco FJ; Shayegan B; Vickers A; Motzer RJ; Bosl GJ; Sheinfeld J
J Urol; 2006 Jul; 176(1):100-3; discussion 103-4. PubMed ID: 16753380
[TBL] [Abstract][Full Text] [Related]
16. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
[TBL] [Abstract][Full Text] [Related]
17. Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors.
Kundu SD; Feldman DR; Carver BS; Gupta A; Bosl GJ; Motzer RJ; Bajorin DF; Sheinfeld J
J Urol; 2015 Feb; 193(2):513-8. PubMed ID: 25150639
[TBL] [Abstract][Full Text] [Related]
18. Predicting necrosis in residual mass analysis after retroperitoneal lymph node dissection: a retrospective study.
Miranda Ede P; Abe DK; Nesrallah AJ; dos Reis ST; Crippa A; Srougi M; Dall'Oglio MF
World J Surg Oncol; 2012 Sep; 10():203. PubMed ID: 23021209
[TBL] [Abstract][Full Text] [Related]
19. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
[TBL] [Abstract][Full Text] [Related]
20. Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumors.
Sheinfeld J; Motzer RJ; Rabbani F; McKiernan J; Bajorin D; Bosl GJ
J Urol; 2003 Oct; 170(4 Pt 1):1159-62. PubMed ID: 14501715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
